DUBLIN, Calif., July 29, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that it will release its 2013 second quarter results on Thursday, August 1, 2013. James S.J. Manuso, PhD, chairman and chief executive officer, and the Astex Pharmaceuticals management team will provide details of the Company's second quarter activities.
A press release will be issued on August 1st at 8:00 a.m. ET. The Company will host a webcast conference call to discuss the results at 8:30 a.m. ET. A live webcast of the call will be available in the Investor Events section of the Company's website at www.astx.com. A webcast replay of the conference call will be available shortly following the event for 30 days.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit www.astx.com.
CONTACT: Timothy L. Enns Astex Pharmaceuticals, Inc. Senior Vice President Corporate Communications & Marketing Tel: +1 (925) 560-2810 E-mail: firstname.lastname@example.org Susanna Chau Astex Pharmaceuticals, Inc. Manager Investor Relations Tel: +1 (925) 560-2845 E-mail: email@example.com Alan Roemer The Trout Group Managing Director Tel: +1 (646) 378-2945 E-mail: firstname.lastname@example.org
Source:Astex Pharmaceuticals, Inc.